<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Anesthesia Progress Blog &#187; American Urological</title>
	<atom:link href="http://www.anesthesiaprogress.com/tag/american-urological/feed" rel="self" type="application/rss+xml" />
	<link>http://www.anesthesiaprogress.com</link>
	<description>Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.</description>
	<lastBuildDate>Sun, 11 Jul 2010 11:29:15 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>American Urological Association: Extended-Release Muscarinic Agonist (Tolterodine) for Overactive Bladder</title>
		<link>http://www.anesthesiaprogress.com/american-urological-association-extended-release-muscarinic-agonist-tolterodine-for-overactive-bladder.html</link>
		<comments>http://www.anesthesiaprogress.com/american-urological-association-extended-release-muscarinic-agonist-tolterodine-for-overactive-bladder.html#comments</comments>
		<pubDate>Fri, 14 May 2010 16:11:17 +0000</pubDate>
		<dc:creator>Andrew</dc:creator>
				<category><![CDATA[Disease]]></category>
		<category><![CDATA[American Urological]]></category>
		<category><![CDATA[Prostate Cancer]]></category>

		<guid isPermaLink="false">http://www.anesthesiaprogress.com/?p=1459</guid>
		<description><![CDATA[Speaker: Jay M. Young, MD, Medical Director, South Orange County Medical Research Center, Laguna Woods, California.
Patients with overactive bladder who received extended-release (ER) tolterodine tartrate (Detrol drug LA, Pharmacia) experienced significantly improved perceptions of urinary urgency and bladder condition, compared with patients who took placebo.
To fully evaluate the benefits of tolterodine treatment, investigators randomly assigned [...]]]></description>
		<wfw:commentRss>http://www.anesthesiaprogress.com/american-urological-association-extended-release-muscarinic-agonist-tolterodine-for-overactive-bladder.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>American Urological Association: Vardenafil for Erectile Dysfunction Irrespective of Prior Sildenafil Use</title>
		<link>http://www.anesthesiaprogress.com/american-urological-association-vardenafil-for-erectile-dysfunction-irrespective-of-prior-sildenafil-use.html</link>
		<comments>http://www.anesthesiaprogress.com/american-urological-association-vardenafil-for-erectile-dysfunction-irrespective-of-prior-sildenafil-use.html#comments</comments>
		<pubDate>Thu, 13 May 2010 16:11:16 +0000</pubDate>
		<dc:creator>Andrew</dc:creator>
				<category><![CDATA[Disease]]></category>
		<category><![CDATA[American Urological]]></category>
		<category><![CDATA[Prostate Cancer]]></category>

		<guid isPermaLink="false">http://www.anesthesiaprogress.com/?p=1458</guid>
		<description><![CDATA[Speaker: William G. Moseley, MD, Medical Director, San Diego Uro-Research, San Diego, California.
Vardenafil (Levitra drug, Bayer/GlaxoSmithKline), a new anti-impotence agent, provided clinically significant, sustained improvement in erectile function over a two-year period in men with erectile dysfunction (ED), whether or not they had previously used the original anti-impotence drug sildenafil (Viagra®, Pfizer).
In a double-blind, multicenter, [...]]]></description>
		<wfw:commentRss>http://www.anesthesiaprogress.com/american-urological-association-vardenafil-for-erectile-dysfunction-irrespective-of-prior-sildenafil-use.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>American Urological Association: Alprostadil Urethral Suppository for Erectile Dysfunction After Radical Prostatectomy</title>
		<link>http://www.anesthesiaprogress.com/american-urological-association-alprostadil-urethral-suppository-for-erectile-dysfunction-after-radical-prostatectomy.html</link>
		<comments>http://www.anesthesiaprogress.com/american-urological-association-alprostadil-urethral-suppository-for-erectile-dysfunction-after-radical-prostatectomy.html#comments</comments>
		<pubDate>Wed, 12 May 2010 16:11:15 +0000</pubDate>
		<dc:creator>Andrew</dc:creator>
				<category><![CDATA[Disease]]></category>
		<category><![CDATA[American Urological]]></category>
		<category><![CDATA[Prostate Cancer]]></category>

		<guid isPermaLink="false">http://www.anesthesiaprogress.com/?p=1457</guid>
		<description><![CDATA[Speaker: Craig Zippe, MD, Staff Surgeon, Section of Urologic Oncology, and Co-Director, Prostate Center and Center for Advanced Research in Human Reproduction, Infertility, and Sexual Function, The Cleveland Clinic, Cleveland, Ohio.
The early use of an alprostadil urethral suppository (Muse®, Vivus, Inc.) in men following bilateral nerve-sparing radical prostatectomy appears to facilitate a rapid return to [...]]]></description>
		<wfw:commentRss>http://www.anesthesiaprogress.com/american-urological-association-alprostadil-urethral-suppository-for-erectile-dysfunction-after-radical-prostatectomy.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>American Urological Association</title>
		<link>http://www.anesthesiaprogress.com/american-urological-association.html</link>
		<comments>http://www.anesthesiaprogress.com/american-urological-association.html#comments</comments>
		<pubDate>Tue, 11 May 2010 16:24:15 +0000</pubDate>
		<dc:creator>Andrew</dc:creator>
				<category><![CDATA[Disease]]></category>
		<category><![CDATA[American Urological]]></category>
		<category><![CDATA[Prostate Cancer]]></category>

		<guid isPermaLink="false">http://www.anesthesiaprogress.com/?p=1456</guid>
		<description><![CDATA[Long-Acting LH-RH Agonist Depot (Leuprolide Acetate) for Prostate Cancer
Speaker: Robert C. Tyler, MD, Director of Clinical Research, Atrix Laboratories, Inc., Fort Collins, Colorado.
A new six-month subcutaneous (SC) depot of leuprolide acetate (Eligard®, Atrix Laboratories, Inc.), a synthetic luteinizing hormone-releasing hormone (LH-RH) agonist, consistently produced and maintained safe and effective serum testosterone suppression. Total serum testosterone [...]]]></description>
		<wfw:commentRss>http://www.anesthesiaprogress.com/american-urological-association.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

